Effect of Sildenafil for the Treatment of Sustained Pulmonary Artery Hypertension After Corrected Mitral Valve Disease

Trial Profile

Effect of Sildenafil for the Treatment of Sustained Pulmonary Artery Hypertension After Corrected Mitral Valve Disease

Active, no longer recruiting
Phase of Trial: Phase II/III

Latest Information Update: 14 Jul 2016

At a glance

  • Drugs Sildenafil (Primary)
  • Indications Pulmonary arterial hypertension
  • Focus Therapeutic Use
  • Acronyms SUPERIOR
  • Most Recent Events

    • 11 Jul 2016 Status changed from not yet recruiting to active, no longer recruiting.
    • 29 Dec 2015 Planned End Date changed from 1 Dec 2017 to 1 Dec 2018 as per ClinicalTrials.gov record.
    • 29 Dec 2015 Planned primary completion date changed from 1 May 2016 to 1 Dec 2017 as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top